House Report Skewers FDA Over Alzheimer’s Drug Approval

Published on December 29, 2022

The approval process for the Alzheimer’s drug Aduhelm has come under fire from a recent congressional report, which highlights numerous irregularities in the review and approval process. It’s like when a sports referee makes questionable calls throughout the game, leaving fans scratching their heads. The report suggests that the FDA may have dropped the ball, allowing potentially ineffective or unsafe drugs to reach the market. This raises concerns about whether patients are being adequately protected and whether the FDA is upholding its responsibility to thoroughly evaluate new medications. To better understand the details and implications of this report, it would be beneficial for interested individuals to read the full investigation. By doing so, readers can gain insight into the specific issues identified by Congress and stay informed about ongoing efforts to ensure the safety and effectiveness of drugs used to treat Alzheimer’s disease.

The Food and Drug Administration’s review and approval process for the Alzheimer’s drug Aduhelm was rife with irregularities, according to a congressional report released Thursday.

Read Full Article (External Site)

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>